Washington, D.C. 20549

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 29, 2024
Humacyte, Inc.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)(I.R.S. Employer
Identification Number)
2525 East North Carolina Highway 54
Durham, NC27713
(Address of principal executive offices)(Zip code)

(Registrant’s telephone number, including area code)
Not Applicable 
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which
Common Stock, par value $0.0001 per shareHUMAThe Nasdaq Stock Market LLC
Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50HUMAWThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 8.01. Other Events.

On February 29, 2024, Humacyte, Inc. (the “Company”) made available an investor presentation (the “Investor Presentation”), which the Company expects to use in connection with investor calls and/or conferences. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 29, 2024
By: /s/ Dale A. Sander
Name:Dale A. Sander
Title:Chief Financial Officer, Chief Corporate Development Officer and Treasurer
Universally Implantable Regenerative Human Tissue 1 Exhibit 99.1

2 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements. All statements, other than statements of historical fact, included in these slides and the accompanying oral presentation are forward-looking statements reflecting management’s current beliefs and expectations. In some cases, you can identify forward-looking statements by terminology such as “will,” “anticipate,” “expect,” “believe,” “intend” and “should” or the negative of these terms or other comparable terminology. Forward-looking statements in these slides and the accompanying oral presentation include, but are not limited to, statements about our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our plans, anticipated timelines and ability to obtain marketing approval from the U.S. Food and Drug Administration (“FDA”) and other regulatory authorities, including the European Medicines Agency, for our bioengineered human acellular vessels (“HAVs”) and other product candidates, including our Biologics License Application seeking approval of the HAV in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and when autologous vein use is not feasible; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials, including for our V007 Phase 3 clinical trial; the outcome of our ongoing discussions with the FDA concerning the design of our clinical trials; our anticipated growth rate and market opportunities; the potential liquidity and trading of our securities; our ability to raise additional capital in the future; our ability to use our proprietary scientific technology platform to build a pipeline of additional product candidates; the characteristics and performance of our HAVs; our plans and ability to commercialize our HAVs and other product candidates, if approved by regulatory authorities; the expected size of the target populations for our product candidates; the anticipated benefits of our HAVs relative to existing alternatives; our assessment of the competitive landscape; the degree of market acceptance of HAVs, if approved, and the availability of third-party coverage and reimbursement; our ability to manufacture HAVs and other product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; our expectations regarding our strategic partnership with Fresenius Medical Care Holdings, Inc. to sell, market and distribute our 6 millimeter HAV for certain specified indications and in specified markets; the performance of other third parties on which we rely, including our third-party manufacturers, our licensors, our suppliers and the organizations conducting our clinical trials; our ability to obtain and maintain intellectual property protection for our product candidates as well as our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights of others; our ability to maintain the confidentiality of our trade secrets, particularly with respect to our manufacturing process; our compliance with applicable laws and regulatory requirements, including FDA regulations, healthcare laws and regulations, and anti-corruption laws; our ability to attract, retain and motivate qualified personnel and to manage our growth effectively; our future financial performance and capital requirements; our ability to implement and maintain effective internal controls; and the impact of the overall global economy and increasing interest rates and inflation on our business. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those risks and uncertainties included under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K filed with the Securities and Exchange Commission on March 24, 2023 and subsequent annual reports, quarterly reports and other filings made with the Securities and Exchange Commission from time to time. Any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

3 Humacyte is a Leader the Field of Regenerative Medicine: Investigational Bioengineered Tissues & Organs Off-the-shelf Universally implantable with no immuno-suppression Observed to regenerate as the patient’s own tissue Category-Defining Innovation that Creates New Tissues

4 Universally Implantable Regenerative Human Tissue Potential First-in-Class Technology & Manufacturing Platform Large addressable markets (trauma, dialysis, peripheral artery disease, diabetes, coronary bypass) Nearing Potential Market Launch BLA granted Priority Review by FDA in February 2024 for HAV in vascular trauma with August 10, 2024 PDUFA date Commercial-Scale Manufacturing Commercial-scale manufacturing in place with annual capacity of up to 40,000 HAVs in existing facility Validated through Multiple Partnerships

5 Humacyte Leadership & Board Leadership Team Board of Directors Kathleen Sebelius Chair of the Board Gordon M. Binder Emery N. Brown, MD, PhD Michael T. Constantino Brady W. Dougan Charles Bruce Green, MD Laura E. Niklason, MD, PhD Todd M. Pope Diane Seimetz, PhD Rajiv Shukla Max Wallace, JD Susan Windham-Bannister, PhD Laura E. Niklason, MD, PhD Founder, President, Chief Executive Officer William Tente, MS Executive Regulatory Fellow Dale Sander Chief Financial Officer, Chief Corporate Development Officer Heather Prichard, PhD Chief Operating Officer BJ Scheessele Chief Commercial Officer Shamik Parikh, MD Chief Medical Officer Sabrina Osborne Executive Vice President, Business Strategy & People Harold Alterson Senior Vice President, Quality Cindy Cao Chief Regulatory Officer Prior Experience

6 Platform & Manufacturing: Enable Broad Pipeline of Regenerative Medicine Products Vascular tissue constructs (HAV) Advanced tissue constructs Advanced organ systems Bioengineering Platform Cell seeding Tissue formation Cell removal and packaging 1 2 3 Working cell stock Cells transferred onto polymer mesh Cells proliferate & build extracellular matrix Polymer mesh degrades, leaving vascular cells and extracellular matrix Decellularization solutions clean and remove vascular cells from vessel Commercial-Scale Manufacturing Strategically designed with modular capabilities to manufacture products at scale Enables creation of universally implantable tissues and organs Our platform technology enables development of a broad range of product candidates

7 Pipeline with Multiple Potential Commercial Launches Preclinical Phase 1/2 Phase 3 Vascular Tissue Constructs (HAV) Trauma Dialysis (AV Access) PAD Pediatric Heart Disease CABG Complex Tissue Constructs Urinary Conduit Tracheal Replacement Esophageal Replacement Complex Organ Systems BioVascular Pancreas (T1D) Lung

HAV Observed to Repopulate with Patient’s Own Cells Potentially Enabling Infection Resistance & Self-Healing More than 500 patients across multiple indications 250 µm αS MA DAP I L umen HAV wall Adventitial layer C apillaries S MC s Host cells observed to repopulate the HAV1 HAV may have the ability to self-heal after host cell repopulation HAV observed to have low rates of infection Off-the-shelf, immediately available with 18-month shelf life No evidence of immunogenicity Long-term durability Resistant to infection even in contaminated wound bed HAV Overview B enefits of HAV 1. Kirkton, R.D., et al, Science Translational Medicine 2019; 11:eaau6934.8

9 Vascular Trauma

10 • Common causes of vascular injuries include workplace injuries, car accidents, gunshots and stabbings, and sports injuries • Currently available treatment options have significant drawbacks: Vascular Injuries – Value Proposition for the HAV 1. Vein is the standard of care, but causes injury from harvest and takes valuable time, delaying revascularization 2. Synthetics are quick, but have infection risk and high rates of amputation Shotgun Wound 3. Amputation

11 • HAV is off the shelf and immediately available for implant • In contrast to harvesting vein from the patient which can take an hour 1 • HAV repopulates with the patient’s cells, becoming a living tissue 2 • HAV is resistant to infection, compared to synthetic grafts 3 Why HAV for Traumatic Vascular Injury? 1: Zenati, M.S., et al, New England Journal of Medicine 2019; 380: 2. 2. Kirkton, R.D., et al, Science Translational Medicine 2019; 11:eaau6934. 3. Wang, J., et al, Journal of Vascular Surgery – Vascular Science 2023; 4: 100120.

12 > Historical Benchmarks > Systematic literature review of synthetics in vascular trauma > Primary Comparison > 30-day endpoint of patency > Secondary Comparisons > Infection rate > Amputation rate Success Criteria > Comparable (or higher) Patency > Infection rate comparable or lower than Synthetic Grafts > Amputation rate comparable or lower than Synthetic Grafts > No unexpected safety signals CLN-PRO-V005 Phase 2/ 3 Pivotal Trial Primary endpoint 30-day patency in patients with extremity injuries • Single-arm, open label trial • Level 1 trauma centers in US and Israel • Arterial injury repair Human Acellular Vessel (HAV) in Vascular Trauma (NCT03005418) • ALL patients had NO VEIN for repair, as assessed by treating surgeons • Hence, patients would have received synthetic grafts, ligation of the bleeding vessel and/or amputation, had they not gotten the HAV. • Extremity Injuries at high risk of contamination/infection1 (NCT03005418)1 69 total patients enrolled as of data cut off 51 patients with extremity injuries – focus for BLA filing 1: Prevaldi et al, 2016 World Journal of Emergency Surgery

13 Example Vascular Injuries Treated in CLN-PRO-V005 Trial Industrial Accident Knee DislocationGunshot Wound

14 Observations from V005 trial:  Secondary Patency • HAV performed better than historic benchmark  Conduit Infections • HAV point estimate lower than historic benchmark  Amputations • HAV performed better than historic benchmark V005 Trial: HAV vs Synthetic Graft Benchmarks Endpoint HAV Extremity (V005) % Synthetic Graft Benchmark % Secondary Patency 90.2% 78.9% Conduit Infections 2.0% 8.4% Amputations 9.8% 24.3% V005 Trial was a Success and Met All Objectives

15 • 19 patients received a HAV • 17 consented for data collection and study participation • 16 patients had extremity trauma repair; one patient required HAV for Iatrogenic Trauma Repair • Ukraine Humanitarian Experience presented at MHSRS1 2023 Annual meeting on August 14th 2023 Ukraine Real World Experience of HAV Use in Vascular Repair 1: MHSRS - Military Health System Research Symposium Measure V017 Trial Ukraine Extremity Patients (n=16) 30-day Patency 93.8% Amputation 0.0% Limb Salvage 100.0% Conduit Infection 0.0% Pre-op CT Scan HAV repair of Femoral artery Ukraine Patient Blast Injury Walking once again (Day 113)

16  Observations from combined V005 and V017 trials:  Secondary Patency • HAV performed better than historic benchmark  Conduit Infections • HAV performed better than historic benchmark  Amputations • HAV performed better than historic benchmark HAV Combined Results from V005 and V017 Trials Endpoint HAV Extremity (V005 + V017 Meta Analysis) % Synthetic Graft Benchmark % Secondary Patency 91.5% 78.9% Conduit Infections 0.9% 8.4% Amputations 4.5% 24.3% Combined V005 + V017 Results Further Supports HAV Performance Versus Synthetic Graft Benchmarks The FDA advised Humacyte to include in its BLA submission patient outcomes from V017 (the humanitarian program conducted in Ukraine)

17 Priority Review of BLA and Planned Market Launch • BLA submitted to FDA in December 2023 • Priority Review granted by FDA in February 2024 • PDUFA date of August 10, 2024 • Factors supporting Priority Review: • In May 2023 the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for use of the HAV in urgent arterial repair following extremity vascular trauma • The HAV was assigned a priority designation by the Secretary of Defense under Public Law 115-92, enacted to expedite the FDA’s review of products that are intended to diagnose, treat or prevent serious or life-threatening conditions facing American military personnel • Planned market launch in 2nd Half 2024 if approved

18 AV Access for Dialysis

19 AV Access for Hemodialysis Has Substantial Limitations Estimates of Access (U.S.) ~20% Grafts ~20% Catheters ~60% AV fistulas Venous / Temporary Catheter Primary/AV Fistula (Autogenous) Secondary / Graft Market targeted by ongoing V007 Phase 3 Trial • ~40% of fistulas fail to mature • Even the fistulas that do mature take 3-6 months to become usable for dialysis • While fistulas are unusable, patients are required to use catheters: • Catheter infection rates are up to 200% per patient-year Limitations of AV Fistulas (Current Standard of Care)

Reduce Costs from Infection HAV is Designed to Address Failures in AV Access Lawson, J.H, et al, The Lancet 2016; 387: 2026-2034. Halbert, R.J., et al, Kidney360 2020; doi: 10.34067/KID.003502020 • HAV usable for dialysis after only four weeks • HAV reduces catheter contact time, thereby reducing risk of catheter infection • >90% of HAVs functional for dialysis at 6 months • HAV infection rate is <1% per patient year • Expected reduction in catheter contact time, infection, and failure rate have potential to reduce costs, including the following: Expected Improved Patient Outcome HAV Expected Economic Benefits RMAT RMAT designation granted by FDA 20 Reduce Costs of Additional Access Procedures

21 > Endpoints > Efficacy: Useability for dialysis and patency during the first year > Safety: interventions, infections, etc. > Duration > Subjects followed for 24 months after implantation > Sites > 30 centers in the U.S. > Timelines > Top-line readout expected in 2024 (12-month follow- up from last subject enrolled) Enrolled Phase 3 Trial in Dialysis: HAV vs. Fistula V007 Phase 3 Trial Design: Compare the Efficacy and Safety of Humacyte’s Human Acellular Vessel with that of an Autologous Arteriovenous Fistula in Subjects with End-Stage Renal Disease HAV• Subjects with end-stage renal disease in need of dialysis and suitable for single-stage arteriovenous fistula • Target 240 total subjects Single-stage AV Fistula in Upper Extremity Trial enrollment completed (242 patients) in April 2023

Supportive Data From Completed Phase 2 & Phase 3 Studies of HAV 1. Woods ide, K enneth J ., et. Al, American J ournal of K idney Dis eas es , Volume 71, Is s ue 6, 2018, P ages 793-801 2. Allon, M., et al. American J K idney Dis eas e 2018; 71: 677-689 3. Arhuides e, et al, 2018; J VS 4. L ok, et al; 2013 C J AS N HAV clinical results Fistula, published data, not head-to-head Fi st ul a 4 Fi st ul a 3 Fi st ul a 3 Fi st ul a 2 Fi st ul a 2 Completed studies of HAV as a conduit for hemodialysis compare well to published results for AV Fistula. The V006 trial of HAV was conducted versus ePTFE. It did not meet its primary endpoint, which was secondary patency compared to ePTFE at 18 months. The secondary patency of the HAV was greater than that of ePTFE at 6 and 12 months, but lower at 18 and 24 months. Fi st ul a 1 6024126421 100 80 60 40 20 0 Months U se ab le fo r d ia ly si s ( % ) V0 01 V0 06 V0 03 V0 01 V0 03 V0 01 V0 11 V0 03 V0 11 V0 03 V0 01 V0 01 V0 06 V0 06 V0 06 V0 11 22

23 Peripheral Arterial Disease (PAD)

• Tissue does not receive enough blood flow to survive • If untreated, leads to tissue loss, gangrene, and ultimately amputation Critical Limb Threatening Ischemia • Non-surgical, catheter-based intervention • Surgical bypass Treatment Requires Restoration of Blood Flow 24 Can progress to multiple leg arteries, further reducing circulation For the 40% of PAD patients who do not have an ipsilateral saphenous vein for arterial bypass, HAV may represent a promising means of revascularization and limb salvage 24 Peripheral Artery Disease (PAD)

Current Clinical Experience with HAV in Peripheral Arterial Disease 25 1Piotr Gutowski, et al, 6-Year Outcomes of a Phase 2 Study of Human-Tissue Engineered Blood Vessels for Peripheral Arterial Bypass, JVS: Vascular Science (2023) 2Lauria A, Kersey A, Propper B, et al. Annals of Vascular Surgery. 2022 Apr 6:S0890-5096(22)00180-7 • V002 – 20 patients (EU) • V004 – 15 patients (US) Phase 2 Trials Over 20 U.S. patients with critical limb ischemia treated under FDA Expanded Access program Investigator-sponsored IND • Up to 35 patients with severe PAD at risk of limb loss • Results to be presented 2024 EA Mayo IND • Six-year results from V002 published in Journal of Vascular Surgery – Vascular Science1 • Publication of First Eight Expanded Access Cases in Annals of Vascular Surgery2 • Preliminary results presented at Midwestern Vascular Surgical Society Meeting in September 2023 showing 86% limb salvage rate

26 Expanded Access Case Study: Restoring Mobility with HAV • The HAV was used under compassionate use program in 70-year-old patient with severe vascular disease • No vein was available to perform a bypass, as the vein was previously harvested for a CABG • A right distal superficial femoral artery-to-peroneal artery bypass was performed using an HAV • The patient’s postoperative course was unremarkable • At 1-year follow-up the angiography showed a patent HAV without significant stenosis at the distal anastomosis • Four years after HAV implantation, the patient continues to do well and is walking. This case was included in HAV results in critical limb ischemia presented at VESS meeting in January 2022 Knee joint Staples at incision HAV Angiogram at 1 year Bypass performed using the HAV in patient with severe vascular disease

27 Pipeline: Cardiac Bypass

• Does not require tissue harvest from the patient • Immediately available and avoids morbidity of vein harvest • Particularly important to avoid vein harvest in diabetics, women, and the overweight • Durable and highly uniform in diameter and quality Potentially Transforming CABG Care: Greater Durability, Less Morbidity • Saphenous Vein Graft (SVG) • Harvesting SVG from the patient is painful and complicated: • 41% have persistent numbness • 32% develop infection • 23% have persistent swelling; worse in obese and diabetic patients; 2x worse in women • SVGs do not last long enough: ~33% of patients will require one or more re- grafting procedures during their lifetimes 28 Humacyte’s HAV Surgeons know what they are getting each time

CABG Preclinical Results 29 • Testing of HAV in baboon model has transitioned to right coronary artery (RCA) as distal target • Results showing HAV maintained patency and exhibited host-cell remodeling through six months Next Steps in CABG Development Proceeding to IND enabling non- clinical studies to support first-in- human clinical trials Humacyte HAV in Baboon 29

30 Primate – CABG Angiography – Adaptive Remodeling: 1 Month 3 Months 6 Months Jonas – Left Ventricular Function (%) Pre-Op 1-Month 3-Month 6-Month 70% 73% 74% 73%

31 Pipeline: BioVascular Pancreas

32 Biovascular Pancreas May Deliver Curative Islets to Diabetics • Islets die after injection into the liver, due to lack of oxygen and nutrients • Humacyte’s HAV is being developed as a means to provide oxygen and nutrients to islets that are coated on the outside: “Biovascular Pancreas” (BVP) • Once implanted in the vasculature, blood flow supplies oxygen and nutrients to islets • One 42-cm HAV is expected to accommodate all the islets in an entire human pancreas Blood Flow Supports Islets BVP Implanted In The ArmIslets + HAV = Biovascular Pancreas (BVP) Biovascular Pancreas Vein Artery HAV with islets

Biovascular Pancreas Normalized Glucose in Diabetic Animals • Diabetic rodents implanted with BVPs • All treated animals normalized glucose over time. All sham- treated animals (“No Flow”) remained diabetic 33 Transplant BVP into Vasculature 0 50 100 0 200 400 600 Blood Glucose Levels Day Bl oo d G lu co se (m g/ dL ) BVP (n=5) No Flow (n=3) **** BVP, rat islets Detect Blood Glucose Diabetic Nude Rat Blood Glucose Levels Normal Blood Glucose Han EX, Wang J, Kural M, et al. Journal of Tissue Engineering; 12: 1-18 33

Primate BVP – Islets Survive, and Produce Insulin 34 • In this model, the BVP is produced by harvesting islets from one animal, and creating a BVP comprising human HAV and primate islets • Animal receives the primate-islet BVP into the aorta • 25,600 islet equivalents • Corresponds to a potentially curative number of islets in a human Islets survive for weeks after implantation, continue making insulin (c-peptide).

35 Anticipated Path to Market

36 Our Technology Addresses Compelling Unmet Needs in Attractive Markets Pre-Clinical Trachea Pancreas Esophagus Urinary Conduit Lung Peripheral Arterial Disease (PAD) Vascular Trauma Dialysis AV Access Coronary Artery Bypass Graft (CABG) BT Shunt Clinical Programs Pre-Clinical Vascular Tissue Constructs Complex Tissue Constructs and Organ Systems

37 Preparing for Strong Commercial Launch Majority of trauma vascular repair performed at Level 1 centers Approximately 200 level 1 trauma centers in U.S. Clear call point as majority of cases performed by vascular surgeons Humacyte expects DoD to stockpile for deployment to sites of conflicts Compelling Health Economic Value Proposition for HAV Budget Impact Model expected to support economic benefit of HAV Costs associated with complications in vascular trauma potentially avoided with HAV: Opportunity for incremental CMS and private pay NTAP payment Vascular Trauma is a Concentrated Market Large shareholder with $175 million invested in Humacyte Global collaboration for HAV in trauma, dialysis and PAD Largest provider of renal care services in the U.S. Amputation Infection Harvest Site Infection Experienced Hospital / Surgical Sales Professionals Estimate we can reach market with fewer than 20 sales representatives Direct force expected to secure hospital approvals through VACs and also drive adoption by vascular surgeons Strategic Collaboration

38 Commercial Manufacturing Scale – LUNA200 System Commercial 83,000 sq ft Bioprocessing Facility • Currently operating 8 LUNA200 systems • Annual Capacity expected to exceed 40,000 HAVs • Functionally closed system with state-of-the-art process automation Bioreactor bag Each bioreactor bag contains a single polymer mesh scaffold, seeded with banked human cells 10 bioreactor bags per growth drawer; tubing connects to shared nutritive media Each LUNA200 can produce 200 HAVs per batch (or ~1,000 HAVs annually) 1 Growth drawer LUNA200 System

39 Anticipated 2024 Milestones Vascular Trauma (HAV): • BLA filing acceptance by FDA • FDA approval • U.S. commercial launch Top-line results V007 HAV dialysis (AV Access) Phase 3 trial Publication of Mayo Clinic HAV Phase 2 trial results in severe PAD All milestone dates are only management estimates Vascular Trauma (HAV): • Completion and positive results from V005 Phase 2/3 trial • Positive Ukraine humanitarian trauma results • BLA submission Completion of enrollment of Phase 3 HAV dialysis trial Positive Phase 2 results from PAD trial conducted by Mayo Clinic Preclinical BVP results showing survival and function of islets Completed in 2023 Anticipated for 2024 BioVascular Pancreas (BVP) for type-1 diabetes: • Results from preclinical studies showing survival and function of islets cells in large animals and diabetes models Results from large animal studies of small-diameter HAV in Cardiac Bypass Surgery (CABG) Publications & Presentations (Multiple other clinical and preclinical publications and presentations expected for 2024)

40 The Promise of Regenerative Medicine Broad platform of universally implantable off-the-shelf bioengineered human tissues and organs Bioengineering Platform Platform targets extensive markets across multiple indications Extensive Markets Existing facilities expected to support anticipated commercial launch with room for modular expansion Commercial Scale Manufacturing

Universally Implantable Regenerative Human Tissue Thank You 41